Targeting IL-1β can mitigate ECM degradation and reduce disc cell apoptosis, potentially slowing the progression of IDD. Combination therapy targeting both IL-1β and its downstream pathways could offer more comprehensive protection. Here, IL1B is linked to intervertebral disk degenerative disorder.